Ed Shovelin: PDE Inhibitors Preferentially Affect ADP and TRAP6 Activation
Ed Shovelin, Operations and Engineering Manager at Pplus Medical Limited, shared on LinkedIn:
”CRP-A by Pplus Medical Limited is increasingly becoming a trusted platelet activator for leading researchers around the world, and we’re delighted to highlight the innovative work it helps make possible.
This week we want to share the following work by Professor Gawaz and his team at the Hospital of the University of Tübingen: Effect of phosphodiesterase inhibitors on platelet function.
Hypothesis: PDE2, PDE3 and PDE5 display differential effects on platelet-mediated thrombosis.
Methods: Compare the effects of PDE inhibition by Ibudilast, a non-selective inhibitor of several PDEs with preference towards PDE3, PDE4, PDE10 and PDE11, IBMX, a nonspecific PDE inhibitor and Sildenafil, a potent selective PDE5 inhibitor, respectively, on platelet activation, aggregation and thrombus formation.
How CRP-A was used: CRP-A was used to induce GPVI-mediated platelet activation, aggregation and thrombus formation.
Key Findings: Platelet activation by ADP via P2Y12 and TRAP6 via PAR1 showed a greater response to PDE inhibitors than platelet activation by CRP-A via GPVI”
Title: Effect of phosphodiesterase inhibitors on platelet function
Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz
Read the Full Article on Biochemistry and Biophysics Reports
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 2, 2026, 13:19John Michael Quinn: Prehospital Whole Blood Remains Critical in Trauma Care
-
Apr 2, 2026, 13:04Dario Bongiovanni: ESC Working Group on Thrombosis Consensus Document Is Now Live
-
Apr 2, 2026, 12:52Ashfa Anwar: While The World Is Editing Genes, Sri Lanka Is Still Thawing Plasma for Hemophilia
-
Apr 2, 2026, 11:48Piotr F. Czempik: Effect of Uremia on Platelet-Mediated Clot Strength in Sepsis
-
Apr 2, 2026, 08:22Chokri Ben Lamine: Laboratory Findings and Management of Severe Type 3 von Willebrand Disease
-
Apr 2, 2026, 08:12Heghine Khachatryan: Dementia at the Intersection of Hematology and Hemostasis
-
Apr 2, 2026, 08:03Thomas Pincez: Revised Guidelines Improve Care for Pediatric Immune Thrombocytopenia
-
Apr 2, 2026, 04:47Augustina Isioma Ikusemoro: A Small Antigen with Big Clinical Consequences
-
Apr 2, 2026, 04:28Mohammed Almohammadi: Etiologic Spectrum and Diagnostic Challenges of Hypocellular Marrow Findings